Shares of Agenus Inc. (NASDAQ:AGEN – Get Free Report) have been given an average rating of “Hold” by the six brokerages that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $10.50.
A number of research firms have issued reports on AGEN. HC Wainwright downgraded Agenus from a “buy” rating to a “neutral” rating and cut their price target for the company from $40.00 to $9.00 in a research note on Thursday, July 18th. Jefferies Financial Group reaffirmed a “hold” rating and set a $7.00 target price (up from $3.00) on shares of Agenus in a research report on Friday, July 19th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley lowered their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Finally, Robert W. Baird lowered Agenus from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $8.00 in a report on Friday, July 19th.
Check Out Our Latest Report on Agenus
Institutional Trading of Agenus
Agenus Trading Down 3.6 %
NASDAQ AGEN opened at $5.09 on Tuesday. The company has a market cap of $106.88 million, a P/E ratio of -0.40 and a beta of 1.33. The company has a fifty day simple moving average of $10.89 and a 200 day simple moving average of $11.71. Agenus has a 12-month low of $4.41 and a 12-month high of $31.20.
Agenus (NASDAQ:AGEN – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The firm had revenue of $23.51 million for the quarter, compared to analysts’ expectations of $64.73 million. During the same period in the prior year, the company earned ($4.00) EPS. Sell-side analysts predict that Agenus will post -10.73 EPS for the current year.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
- Five stocks we like better than Agenus
- Industrial Products Stocks Investing
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What is Insider Trading? What You Can Learn from Insider Trading
- 2 Option Strategies to Maximize Profits in a Bear Market
- 3 Warren Buffett Stocks to Buy Now
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.